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Background: Effective eradication of high-risk primary prostate cancer (HRPCa) could significantly decrease
mortality from prostate cancer. However, the discovery of curative therapies for HRPCa is hampered by the lack of
authentic preclinical models.
Methods: We improved upon tumorgraft models that have been shown to predict drug response in other cancer
types by implanting thin, precision-cut slices of HRPCa under the renal capsule of immunodeficient mice. Tissue
slice grafts (TSGs) from 6 cases of HRPCa were established in mice. Following androgen deprivation by castration,
TSGs were recovered and the presence and phenotype of cancer cells were evaluated.
Results: High-grade cancer in TSGs generated from HRPCa displayed characteristic Gleason patterns and
biomarker expression. Response to androgen deprivation therapy (ADT) was as in humans, with some cases
exhibiting complete pathologic regression and others showing resistance to castration. As in humans, ADT
decreased cell proliferation and prostate-specific antigen expression in TSGs. Adverse pathological features of
parent HRPCa were associated with lack of regression of cancer in corresponding TSGs after ADT. Castration-resistant
cancer cells remaining in TSGs showed upregulated expression of androgen receptor target genes, as occurs in
castration-resistant prostate cancer (CRPC) in humans. Finally, a rare subset of castration-resistant cancer cells in TSGs
underwent epithelial-mesenchymal transition, a process also observed in CRPC in humans.
Conclusions: Our study demonstrates the feasibility of generating TSGs from multiple patients and of generating a
relatively large number of TSGs from the same HRPCa specimen with similar cell composition and histology among
control and experimental samples in an in vivo setting. The authentic response of TSGs to ADT, which has been
extensively characterized in humans, suggests that TSGs can serve as a surrogate model for clinical trials to achieve
rapid and less expensive screening of therapeutics for HRPCa and primary CRPC.
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Mortality from prostate cancer (PCa) is confined to
those men who have either advanced disease (distant
metastases at initial presentation) or high-risk localized
PCa (HRPCa) [1,2]. The definition of HRPCa is either a
Gleason score of 8–10, pre-treatment serum prostate-
specific antigen (PSA) > 20 ng/ml, or clinical stage of
T3/T4 at diagnosis [3]. In addition, patients with at least
two of the following criteria - a Gleason score of 7, pre-* Correspondence: dpeehl@stanford.edu
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reproduction in any medium, provided the ortreatment serum PSA > 10 ng/ml, and a clinical stage of
T2b/c - may also be considered high-risk [3]. Since < 5%
of patients with newly diagnosed PCa have advanced
metastatic disease, HRPCa, which comprises 15-40% of
the overall PCa patient population, has become an im-
portant focus of novel therapeutic development [4,5].
Androgen receptor (AR) signaling plays a central role
in all stages of PCa. For HRPCa, the standard of care is
either radical prostatectomy or radiation therapy combined
with androgen-deprivation therapy (ADT) [5-8]. In
spite of treatment, up to 50% of these high-risk patients
will inevitably progress to castration-resistant prostatetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[6,9-11]. One of the key mechanisms of resistance to
ADT is the continued expression of AR by most CRPC
and dependence on AR for growth [7-9,12]. Moreover,
ADT induces epithelial-mesenchymal transition (EMT),
a process that has been associated with aggressive clin-
ical behavior in human PCa [13,14].
New primary therapies that can be used to eradicate
HRPCa alone or in combination with ADT before CRPC
arises, or to treat primary CRPC effectively after ADT,
are urgently needed. Because experimental models of
primary human PCa are extremely limited, new genera-
tions of compounds targeting AR signaling at different
levels as well as other essential pathways in PCa have
been developed using pre-clinical models of metastatic
CRPC [15-18]. Whether these agents will be effective
against primary HRPCa and derivative CRPC is not
known. A realistic and representative in vivo model of
HRPCa and primary CRPC is critical for pre-clinical
assessment and comparison of different treatment options.
Such a model will not only accelerate the discovery of
effective therapies by minimizing the number of costly
and time-consuming clinical trials, but also help enhance
our understanding of mechanisms of therapeutic resistance.
Remarkable correlations between drug activity in
“tumorgrafts” derived directly from patient tissues and
clinical outcomes have been observed [19,20]. For instance,
Hidalgo et al. demonstrated a notable correlation be-
tween drug activity in patient-derived tumorgrafts and
clinical outcome in 14 types of advanced cancers [20].
Multiple groups have reported the ability to establish
PCa tumorgrafts in mice under the skin or renal cap-
sule, often through the use of minced pieces of tissue
[21-25]. When minced fragments of tissue are used to
generate grafts, it is impossible to know the compos-
ition of any given fragment (or even whether it contains
cancer), due to the heterogeneous nature of prostate
tissue. This, in turn, makes it impossible to ensure that
tissues with similar composition are used in control
and experimental groups, which, in turn, confounds
interpretation of results. In addition, it is difficult to
generate enough grafts from a single prostatectomy
specimen to carry out experiments to test drugs with
sufficient statistical power. Unfortunately for PCa research,
metastatic tissue is also very difficult to obtain, and
access to such tissue is predominantly limited to the
few academic programs that support “rapid autopsy”
programs. For all of the reasons stated above and more,
tumorgrafts of PCa are not often included in studies
such as that described above by Hidalgo et al. with
multiple types of cancers (but no PCa) [20].
We developed methodology to establish tumorgrafts
from thin, precision-cut tissue slices of human PCa to
overcome at least some of the problems [26]. This novelin vivo tissue slice graft (TSG) model: 1) retains PCa
histopathology, allowing for analysis of almost all of
the cell types present in PCa and their interactions; 2)
provides accurate assessment of the effects of interven-
tions when tissues from the same specimen with similar
cell composition are used as control and experimental
samples; 3) ensures sufficient samples obtained for large
experiments; and 4) permits optimal exchange of nutri-
ents, oxygen, and drugs between TSG and the host.
Here we characterized TSGs generated from 6 HRPCa
cases as well as the castration-resistant cancer that
remained in TSGs from 3 of 5 cases after ADT. We
focused on high-grade components of the tumors as the
likely cause of recurrence and/or castration-resistance
after primary therapy. The main questions we addressed
were whether cancers in TSGs maintained in intact mice
retained the histology and biomarker expression of parent
tumors, and whether androgen deprivation affected cell
proliferation, AR-regulated gene expression and EMT
of cancers in TSGs similarly to that in humans. We
provide evidence that TSGs are the first realistic model
of primary HRPCa and CRPC that can be used with
high predictive power to evaluate an exponentially grow-
ing number of molecularly targeted therapies and to




All animal studies were approved by the Stanford Ad-
ministrative Panel on Laboratory Animal Care (APLAC)
and done in compliance with the regulations for animal
studies at Stanford University. Patient-derived tissues
were obtained immediately after surgery under a protocol
approved by the Stanford Institutional Review Board.
The participants provided their written informed consent
to participate in this study.
Patient samples
Clinical and histopathologic parameters of the donors
are summarized in Table 1. None of the patients had
chemical, hormonal, or radiation therapy prior to radical
prostatectomy.
Precision-cutting and subrenal implantation of
tissue slices
Male recombination activating gene-2 (RAG2)−/−γC−/−
mice bred at Stanford University or NIH III mice
(Charles River, Wilmington, MA, USA) between 6 and 8
weeks of age were used. All animal studies were done
in compliance with regulations at Stanford University.
Precision-cutting and subrenal implantation of tissue
slices were described previously [26]. A 25-mg testos-
terone pellet with a release rate of 0.2 mg/day was
Table 1 Clinical and histopathologic variables of tissue donors
ID Pre-op
PSA ng/ml
Gleason score Clinical stage Pathological stage SV1 SM2 ECE3
Biopsy Prostatectomy
HRPCa-1 38.48 4+3 4+3 cT1c pT3bN0 + - +
HRPCa-2 8.5 4+4 4+5 cT1c pT3bN1 + + +
HRPCa-3 4.6 4+3 3+4 cT2b pT3aN0 - + +
HRPCa-4 36 4+3 4+4 cT2b pT3bN1 + + +
HRPCa-5 6.07 4+5 3+4 cT2b pT2cN0 - - -
HRPCa-6 2.09 4+5 3+4 cT2b pT2bN0 - - -
1 seminal vesicle invasion.
2 surgical margin.
3 extracapsular extension.
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between the shoulder blades.Castration of mice
Castration of mice was performed one month after
subrenal implantation as previously described [26].Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed [26]. Antigen retrieval was achieved by heating
in citrate buffer (pH 6.0) for 20 minutes, followed by a
20-minute cool-down. The sources and dilutions of the
antibodies used in this study are listed in Table 2.Table 2 Antibodies used in the study
Name Source Dilution






Anti-PSA Santa Cruz Biotechnology 1:100
Anti-AMACR/p63 Biocare, Concord, CA ready to
use
Anti-Ki67 Biocare 1:100
Anti-Ku70 Abcam, Cambridge, MA 1:200




Anti-ERG Epitomics, Burlingame, CA 1:100
Anti-VIM Epitomics 1:100






Alexa 488 goat anti-mouse Invitrogen, Carlsbad, CA 1:1000
Alexa 555 goat anti-rabbit Invitrogen 1:1000Quantitation of Ki67 and CCNA expression
The proliferation index, defined as percentage of prolif-
erating cells, was established by dividing the number
of Ki67-positive cells by the total area of cancer (based
on histology and/or AMACR expression) in ten 20X-
microscopic fields, randomly chosen for each TSG.
Similarly, the percentage of CCNA-positive cells was
determined by dividing the number of CCNA-positive
cells by the total area of cancer in five 20X-microscopic
fields for each TSG. Student’s t-test with a significant level
set at α < 0.05 was performed to determine statistical
significance.Results
Generation of TSGs from HRPCa
We generated 6–10 TSGs from each of 6 fresh HRPCa
tissues obtained immediately following radical prostatec-
tomy (Tables 1 and 3). Since high-grade cancer is likely
the cause of recurrence after primary therapy, we excised
tissues from areas containing mainly Gleason grade 4 and/
or 5 cancer based on the ultrasound-guided prostate
needle biopsy map obtained prior to surgery. While
cutting at 300-μm, every other slice was frozen, sectioned,
and stained with H&E to confirm histopathology. Only
slices that were in-between two slices containing high-









HRPCa-1 101 NA 10 NA
HRPCa-2 5 3 5 3
HRPCa-3 3 3 3 3
HRPCa-4 5 5 5 3
HRPCa-5 4 5 4 0
HRPCa-6 4 4 4 0
1TSGs were harvested one month after implantation. All other TSGs were
harvested two months after implantation.
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tumor, HRPCa-1, but maintained in two mouse strains,
RAG2−/−γc−/− [27,28] and NIH III [29,30]; both lack T, B,
and natural killer cells but the extent of the deficiencies
in each has not been established. Although the grossFigure 1 Generation of TSGs from HRPCa-1 and −2. (A) Kidneys with T
(B) both the graft weight and proliferation index of TSGs maintained in RA
NIH III mice by Student’s t-test; (C-H) immunohistochemistry of TSGs in RA
human-specific CD31 (E and G), and human-specific Ku70 (F and H). (E-F)
Arrows in (D) and (E and G) point to Ki67- and CD31-positive cells, respect
mouse kidney and TSG. Magnification for (C) and (D) is 10X and (E-H) is 40appearance of TSGs maintained in both hosts for 1
month was similar (Figure 1A), the average graft weight
and the proliferation index of cancer in RAG2−/−γc−/−
mice were significantly higher than in NIH III mice
(Figure 1B). Serial sections were stained with antibodiesSGs under the capsule harvested from RAG2−/−γc−/− or NIH III mice;
G2−/−γc−/− mice were significantly higher than those maintained in
G2−/−γc−/− mice using antibodies against AMACR/p63 (C), Ki67 (D),
are control TSGs and (G-H) are TSGs one month after castration.
ively. White dotted lines in (F) and (H) mark the boundary between
X.
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label proliferating cells (Figure 1C-D). The proliferation
index in TSGs maintained in RAG2−/−γc−/− mice was
97% of the parent tumor. These results suggest that
RAG2−/−γc−/− mice provide a more supportive environment
for TSGs derived from HRPCa than NIH III mice and
should be the host of choice for human PCa tumorgrafts.
Immunohistochemistry using human-specific CD31
antibody demonstrated that a considerable amount of
the vasculature present in HRPCa TSGs two months
following implantation was lined by endothelial cells of
human origin, consistent with previous findings [25,26,31].
Representative images from HRPCa-2 are shown in
Figure 1E. In addition, most of the stromal cells in TSGs
are of human origin as demonstrated by labeling with an
antibody against human-specific nuclear antigen Ku70
(Figure 1F). Similar results were observed in TSGs derived
from the same parent tumor one month after castration
(Figure 1G-H), demonstrating the persistence of human
endothelial and stromal cells in prostate TSGs.
TSGs derived from HRPCa resembled the parent tumors
We compared the histology and protein expression of
cell type-specific markers in TSGs to the parent tumors.Figure 2 Marker expression in HRPCa-2 by immunohistochemistry. In
(A-B) strong cytoplasmic K18 staining; (C-D) nuclear staining of AR; (E-F) cy
basal cell marker p63; positive staining for cytoplasmic AMACR (G-H) and n
the same specimen, we observed nuclear ERG expression in low-grade can
epithelial cells (arrows in L). (B), (D), (F), (H), and (J) are higher magnificatio
The ERG-positive cells in (J) are endothelial cells, not cancer cells.HRPCa-2, a parent tumor, expressed classic secretory cell
markers including cytoplasmic K18 (Figure 2A-B), nuclear
AR (Figure 2C-D), and cytoplasmic PSA (Figure 2E-F). In
contrast, the tumor was negative for the basal epithelial
cell marker p63 (Figure 2G-H). Moreover, the area where
the tissue was taken for TSG generation was positive for
AMACR (Figure 2G-H) but negative for ERG (Figure 2I-
J), two markers widely used to identify PCa in humans.
AMACR is expressed by ~90% of PCa [32] and is used
to identify PCa in clinical specimens. Expression of
ERG is highly correlated with the presence of the
TMPRSS2-ERG gene fusion present in ~50% of PCa and
is negatively correlated with Gleason score (i.e., high-grade
PCa is less likely to express ERG) [33]. Consistent with the
negative correlation between ERG expression and Gleason
score, we observed ERG expression in grade 3 cancer
in the same prostatectomy specimen (Figure 2K) as
well as p63 staining in normal basal cells (Figure 2L),
demonstrating that absence of staining in the area
where the tissue was taken was not attributable to tech-
nical failure.
TSGs derived from HRPCa-2 harvested two months
after implantation showed similar histomorphology to
the parent tumor. Specifically, high-grade cancer wasthe area where tissue cores were taken to derive TSGs, we observed:
toplasmic staining of PSA; (G-H) negative staining for the normal
egative ERG (I-J). In areas away from where tissue cores were taken in
cer cells (arrows in K) and staining for nuclear p63 in normal basal
n (40X) of boxed areas in (A), (C), (E), (G), and (I) (10X), respectively.
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irregular mass of neoplastic cells with little or no gland
formation (Figure 3). In addition, TSGs displayed similar
expression of cell-type specific markers to the parent
tumor (Figure 3A-J). TSGs from the other five HRPCa
specimens also displayed similar histomorphology and
marker expression as their parent tumors (Table 4). For
example, both HRPCa-1 and its derived TSGs were
strongly positive for ERG (Figure 3K-L) and AMACR
(Figure 3M-N). Overall, these results demonstrated that
high-grade cancer from HRPCa maintained appropriate
histomorphology and protein expression in TSGs up to
2 months post-implantation.
Adverse pathological features of parent tumors predicted
response of TSGs to ADT
Of the 6 cases used in this study, ADT was performed in
5 cases since HRPCa-1 was used for comparison of host
mouse strains only. Two of the cases (HRPCa-5 and −6)
were down-graded on final pathology of the radical pros-
tatectomy specimens to Gleason score 7 from 9 and had
no adverse pathological features such as positive surgical
margin, seminal vesicle invasion, or extracapsular exten-
sion (Table 1). For accurate assessment effects of ADT,
we assigned mice bearing TSGs derived from adjacent
tissue slices into control and ADT groups. Interestingly,
one month after ADT, cancer cells were found in 60-
100% of the TSGs derived from HRPCa-2, -3, and −4
(Table 3). These TSGs were defined as castration-resistant
TSGs (CR-TSGs). In contrast, no cancer cells were de-
tected in TSGs derived from HRPCa-5 and −6, demon-
strating complete tumor regression after ADT (Table 3).
For example, TSGs derived from HRPCa-3 expressed a
high level of AMACR in both control and castrated mice
(Figure 4A-B), whereas AMACR-expressing cancer cells
were only observed in TSGs derived from HRPCa-6
maintained in control but not castrated mice (Figure 4C-
D). TSGs were sectioned throughout to confirm complete
pathologic response to ADT (absence of AMACR-stained
cells and no recognizable cancer by histopathological
analysis). These results mimicked the heterogeneous
response of HRPCa in patients to ADT, and suggest
that adverse features of parent tumors may predict the
response of TSGs to ADT.
ADT modulated AR-regulated genes in TSGs similarly to
PCa in humans
After ADT, remaining cancer cells in CR-TSGs derived
from HRPCa-2 demonstrated similar histological features
and biomarkers to those in control TSGs, including
expression of AR (Figure 3O-P). As expected, these
cells showed little or no staining for PSA (Figure 3Q-R),
consistent with the response of PCa in humans to ADT
[34]. Cancer cells were also positive for K18 (Figure 3S-T) and AMACR (Figure 3U-V), and negative for ERG
(Figure 3W-X). These results suggest that ADT abolished
PSA expression in cancer cells in CR-TSGs derived
from HRPCa but did not affect expression of other
markers.
We next examined the expression of AR-regulated genes
that have been reported to be up-regulated in human
CRPC including TOP2A and CCNA [35]. In CR-TSGs
derived from HRPCa-4, the expression level and percent-
age of TOP2A-positive cells was significantly higher com-
pared to control (Figure 5A-B). ADT also increased the
percentage of CCNA-expressing cancer cells in CR-TSGs
by 2.4-fold compared to control (Figure 5C-D, 5G). These
results demonstrated that TSGs derived from HRPCa
responded to ADT by upregulating AR target genes as-
sociated with CRPC in humans. Moreover, the number
of Ki67-expressing cells in CR-TSGs was significantly
lower than that in control (Figure 5E-G), consistent
with the observation that ADT inhibits cell proliferation
in PCa in humans [36]. Few or no apoptotic cells were
detected in CR-TSGs by cleaved caspase-3 staining
(data not shown); if apoptosis was induced by ADT, it
may have occurred rapidly after castration and diminished
by one month after castration. Similar results were ob-
served for HRPCa-2 (Figure 5H) and −3 (Figure 5I).
Together, these findings demonstrated an authentic
response to ADT of HRPCa in TSGs similar to that oc-
curs in humans, suggesting that CR-TSGs realistically
model primary CRPC.
ADT induced EMT in CR-TSGs similarly to human PCa
To determine the effects of ADT on EMT in TSGs and
compare to its effects in PCa in humans, we examined
EMT marker expression in three human prostates re-
moved by radical prostatectomy following neoadjuvant
ADT (Flutamide or Lupron treatment of 6 to 10 weeks
in duration) and two untreated specimens as controls. In
untreated PCa, high-grade cancers of Gleason patterns 4
and 5 showed strong cytoplasmic expression of K18
(Figure 6A), a classic epithelial cell marker. Expression
of VIM, a mesenchymal marker whose expression is
increased in epithelial cells during EMT, was only
observed in stromal cells (Figure 6B) and mutually
exclusive from K18 expression (Figure 6D). In contrast,
a small population of high-grade PCa cells expressed
both K18 (Figure 6E) and VIM (arrows in Figure 6F
and 6H) in specimens treated with ADT. Although
VIM-positive, these cells still maintained epithelial cell
morphology, i.e., cuboidal rather than spindle-shaped.
These results suggest that a subset of high-grade pros-
tate cancer cells in humans treated with ADT under-
went EMT.
A similar staining pattern was observed in CR-TSGs
derived from HRPCa-2, -3 and −4. Specifically, a rare
Figure 3 Marker expression in TSGs derived from HRPCa-2. In control TSGs derived from HRPCa-2, we observed: (A-B) nuclear staining of AR;
(C-D) cytoplasmic staining of PSA; and (E-F) cytoplasmic staining of K18 in cancer cells. Positive staining of AMACR (G-H), and negative staining
of the basal epithelial cell marker p63 (G-H) and ERG (I-J) in cancer cells was also observed. ERG staining was present in endothelial cells (I-J). In
CR-TSGs derived from HRPCa-2, cancer cells showed moderate nuclear staining for AR (O-P), little or no staining of PSA (Q-R), and intense
cytoplasmic staining for K18 (S-T). Cancer cells were also positive for AMACR (U-V) and negative for ERG (W-X). In HRPCa-1 and TSGs derived
from it, we observed strong staining for ERG (K-L) and AMACR (M-N) in cancer cells. (B), (D), (F), (H), (J), (P), (R), (T), (V), and (X) are higher
magnifications of boxed areas in (A), (C), (E), (G), (I), (O), (Q), (S), (U) and (W), respectively.
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Table 4 Marker expression in HRPCa where tissues were
taken for TSG generation and in corresponding TSGs
ID K18 AR PSA AMACR P63 ERG
HRPCa-1 + + + + - +
Derivative TSGs + + + + - +
HRPCa-2 + + + + - -
Derivative TSGs + + + + - -
HRPCa-3 + + + + - -
Derivative TSGs + + + + - -
HRPCa-4 + + + + - -
Derivative TSGs + + + + - -
HRPCa-5 + + + - - -
Derivative TSGs + + + - - -
HRPCa-6 + + + + - -
Derivative TSGs + + + + - -
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K18 was observed in CR-TSGs (Figure 6M-P) but not
in control TSGs (Figure 6I-L). Moreover, E-cadherin, a
well-known epithelial marker, was primarily localized
on the cell membrane in cancer cells of control TSGs,
while in CR-TSGs, it was mislocalized away from the
cell membrane into the nucleus (Figure 7). This leads
to loss of function of E-cadherin, commonly observed
during EMT [37,38]. These results suggest that ADT
induced EMT in the TSG model similar to CRPC in
humans.Figure 4 Differential responses to ADT of TSGs derived from HRPCa w
Immunohistochemistry using an antibody cocktail for cytoplasmic AMACR
adverse pathological features, to ADT (A-B), and complete tumor regressio
ADT (C-D). In (D), remnant epithelial cells are benign, as demonstrated by
mouse kidney and TSG. Magnification for all images is 40X.Discussion
We have shown that TSGs derived from HRPCa re-
capitulate characteristics of parent tumors including
histopathological features, biomarker expression, and
responses to ADT. Our study differs from previous
reports [21-26] of generation of prostate tumorgrafts in
several ways. First, we implanted precision-cut tissue
slices rather than minced tissues as used in previous
studies. The ability to reliably determine the presence
and grade of cancer prior to implantation is one of the
advantages of this methodology, which in turn allows
more accurate assessment of therapeutic effects in large-
scale animal trials. For example, our study design ruled
out the possibility that “bad” tumors were missed in the
two cases that showed complete regression after castra-
tion. Because we used only slices that were in-between
two slices containing high-grade PCa and assigned
adjacent tissue slices to control and ADT groups, it is
unlikely that the “bad” tumors were missed only in the
ADT but not the control group. If minced tissues were
used without prior knowledge of histopathology, it
would be impossible to know whether the complete
regression was just by chance, i.e., the bad tumors were
missed or there was no cancer present initially in the
ADT group. Second, we focused on high-risk tumors,
the major contributor to PCa mortality, rather than
benign or low-risk tumors that have been used in most
previous studies. Third, we systematically evaluated the
effects of ADT, a standard treatment for HRPCa, in ourith or without adverse pathological features.
and nuclear p63 demonstrated resistance of HRPCa-3, a HRPCa with
n in HRPCa-6, a HRPCa without adverse pathological features, after
nuclear p63 staining. White dotted lines mark the boundary between
Figure 5 Effects of ADT on AR target genes, cell proliferation, and graft weight in HRPCa-4 TSGs. ADT dramatically increased the
expression of TOP2A in CR-TSGs (B) compared to control (A). Similarly, the number of CCNA-positive cells was 2.4-fold higher in CR-TSGs (D) that
in control TSGs (C). Ki67-positive cells were dramatically decreased in CR-TSGs (F) compared to control TSGs (E). This decrease was statistically
significant as was the decrease in graft weight in response to ADT by Student’s t-test (G). ADT also decreased cell proliferation and upregulated
CCNA expression in HRPCa-2 (H) and HRPCa-3 (I). The values in castrated TSGs were normalized against control. * marks significant difference
between castrated and control TSGs defined as p<0.05 by Student’s t-test.
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small, it is the largest cohort of HRPCa evaluated for
response to ADT to date in a preclinical model.
HRPCa is the target of adjuvant and neoadjuvant
therapies since low-risk PCa is largely curable by surgery
or radiation or needs no treatment. A growing inventory
of new agents has been discovered that may improve the
clinical outcome of HRPCa. Clinical trials evaluating such
candidate compounds require a large number of patients,are expensive and time-consuming, and expose patients to
certain risks. The TSG model of HRPCa provides a much-
needed pre-clinical screening platform that can be used to
rapidly narrow down the number of agents or regimens
for further investigation in clinical trials. The authenticity
of the model in recapitulating the features of the parent
tumors increases confidence in the likelihood of similar
drug responses in humans. In addition, our study dem-
onstrates the feasibility of generating a relatively large
Figure 6 ADT induced expression of VIM in PCa cells. Double immunofluorescent staining showed that in human hormone-naive PCa,
high-grade cancer cells showed strong cytoplasmic expression of K18 in green (A) and no expression of VIM (B). VIM staining in red was present
in the tissue (mostly in cytoplasm of stromal cells) but was exclusive from K18-positive cells (B and D). In contrast, in human PCa treated with
ADT, a small population of high-grade PCa cells expressed both K18 (E) and VIM (arrow in F) as shown in the merged image (arrow and insert
in H). In control TSGs derived from HRPCa-2, K18 (I) and VIM (J) displayed mutually exclusive staining (L). In CR-TSGs, a rare population of cancer
cells expressing both VIM (arrow in N) and K18 (M) was observed in the merged image (arrow and insert in P). (C), (G), (K), and (O) showed
nuclear DAPI staining of the same cells in (A-B), (E-F), (I-J), and (M-N), respectively. Magnification for all images is 40X.
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similar cell composition and histology among control
and experimental samples in an in vivo setting. This
capability is particularly useful since PCa specimens are
becoming smaller due to early cancer detection. Our
model can be used to test a variety of therapeutic strat-
egies, including potential curative therapies for HRPCa
that can either prevent CRPC from arising during ADT or
kill CRPC cells after disease progression. Since ADT may
be associated with numerous side effects such as increased
cardiovascular mortality, other alternative therapies should
also be investigated [39]. Finally, our model can be used
to better understand the mechanisms of development
of CRPC, which will in turn accelerate the discovery of
effective therapies.
As proof-of-principle, we have demonstrated that our
model closely mimics the response of PCa in humans toADT. First, ADT decreased cell proliferation and reduced
graft weight of TSGs. Second, ADT downregulated the
conventional AR target gene PSA while selectively
upregulating CCNA and TOP2A in CR-TSGs, as in
human PCa [35], suggesting that the TSG model is a
suitable platform for pre-clinical testing of the ever-
growing number of new therapeutic agents that aim to
better prevent AR activation in CRPC. Third, consistent
with recent studies highlighting a role for EMT after
ADT in facilitating human PCa progression and metasta-
sis [14,40,41], cancer cells in CR-TSGs exhibited EMT
by simultaneously expressing both mesenchymal and
epithelial cell markers, VIM and K18, respectively. In
addition, E-cadherin was mislocalized away from cell
membranes into the nuclei in CR-TSGs, presumably
disrupting the function of E-cadherin in preventing
beta-catenin from entering the nucleus [38]. Such
Figure 7 ADT induced mislocalization of E-cadherin in TSGs derived from HRPCa-2. E-cadherin, a well known epithelial marker, was
primarily localized on cell membranes in cancer cells of human hormone-naive PCa (A) and control TSGs derived from HRPCa-2 (C), while in
human PCa treated with ADT (B) and castrated TSGs (D), it was mislocalized away from the cell membrane (arrow in C) into the nucleus (arrow
in D). The inserts are enlarged images of the boxed area in each image. Magnification for (A) and (B) is 40X, and for (C) and (D), 20X.
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colorectal cancer model in which E-cadherin nuclear
translocation was associated with aggressive focal growth
[42], suggesting that mislocalization of E-cadherin may
be a general mechanism of cancer progression. The
documentation of ADT-induced EMT in CR-TSGs
derived from HRPCa suggests an attractive model for
testing novel therapeutics aimed at blocking EMT.
Our findings are the first to link seminal vesicle inva-
sion, positive surgical margin and extracapsular extension
to lack of complete pathologic response to ADT by
HRPCa. The efficacy of neoadjuvant ADT in the TSG
model appears much better than in patients determined
by histology [43,44]. Since the presence or absence of
tumor cells in TSGs was evaluated one month after
castration, we can’t rule out the possibility that the
regressed tumors might relapse at later time points. In
addition, most studies show a lower serum testosterone
level in castrated mice than in humans [26,45-47], possibly
because unlike in humans, adrenal glands in mice do
not produce androgen [48-50]. Thus, castration of mice
may more effectively eliminate HRPCa cells in TSGs
than does ADT in humans. Further experiments are
needed to determine the long-term effects of ADT and
to investigate the possibility of serial passage in this
model. Mechanisms of resistance to therapy can be
explored, such as the role of stem cells in castration-
resistance.
It is interesting to note that endothelial and stromal
cells in TSGs are mostly of human origin, rather than
replaced by their host counterparts. This is consistent witha recent report demonstrating a burst of angiogenesis by
endogenous human blood vessels in primary xenografts of
benign prostate or PCa tissues that occurred between days
6–14 after transplantation into SCID mice pre-implanted
with testosterone pellets [25]. In contrast, DeRose et al.
demonstrated that, in human breast tumorgrafts, cancer-
associated stroma and endothelial cells from the original
tumor were largely replaced by mouse-derived stroma
and endothelial cells [51]. This difference may be due
to the disparate growth properties of these two types of
cancers − PCa is a slow-growing cancer with a long
natural history, whereas breast cancer is much more
aggressive. The slow-growing nature of prostate TSGs
perhaps makes it unnecessary to incorporate host stromal
and endothelial cells in the grafts. In our study, human
stromal and endothelial cells survived up to 2 months
in TSGs derived from HRPCa. It would be interesting
to determine whether the human endothelial and stromal
cells would eventually be replaced by their mouse counter-
parts in long-term follow-up of these grafts.
Conclusions
We provide evidence that TSGs are a realistic model
of primary HRPCa and CRPC that may be used with
high predictive power to evaluate the exponentially
growing number of molecularly targeted therapies and
to discriminate the most effective therapeutics for fur-
ther clinical development.
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